Students are advised to consult the supervisors regarding the respective research topic.
| Supervisor | Research topic |
|---|---|
| Baghy Kornélia MD | The role of the SPOCK1 proteoglycan in tumor development and progression |
| Gábor Barna MD | MRD measurement in Multplex Myeloma with new generation flow cytometry |
| Investigation of CD180 expression in acute leukaemias | |
| Changes in T cell subpopulations in patients with multiple myeloma treated with mesigdomid | |
| Csaba Bödör MD | Genomic characterization of adult and pediatric hematological malignancies |
| Katalin Dezső MD | The importance of genetic diversity in the human liver during regeneration and chronic liver diseases |
| László Fónyad MD | The role of the SPOCK1 proteoglycan in tumor development and progression |
| Noémi Jákob MD | Research on progression, prognostic, and predictive biomarkers of recurrent oral squamous cell carcinomas |
| Richárd Kiss MD | Molecular profiling of childhood sarcomas |
| Árpád Ferenc Kovács MD | Investigation of T cells in the development and progression of cardiomyopathies |
| Ilona Kovalszky MD | The role of the SPOCK1 proteoglycan in tumor development and progression |
| Tibor Krenács MD | Prognostic factors in triple negative breast cancer |
| Ildikó Krencz MD | Investigation of targeted therapeutic options in small cell lung carcinomas |
| Ágnes Márk MD | Investigation of CD49f isoforms in B-cell acut lymphoblastic leukemia |
| Tamás Mícsik MD | Clinicopathological examination of adrenocortical carcinoma |
| Retrospectiv clinicopathological investigation of neuroblastomas | |
| Clinicopathological and digital pathological examination of Wilms Tumors | |
| Colorectal carcinoma and the SPOCK1-protein | |
| Digital pathological examination and prognostication of colorectal carcinomas | |
| Metabolomics of carcinomas | |
| Digital pathological examination and prognostication of renal cell cancers | |
| Subclassification of endometrial carcinomas with AI | |
| Réka Mózes MD | Clinicopathological and genetic characterization of myeloproliferative neoplasms |
| Hajnalka Rajnai MD | Modern pathological diagnostics of childhood central nervous system tumors |
| Eszter Regős MD | Morphometric studies on tissue samples from recurrent first trimester miscarriage |
| András Rókusz MD | Pathology of molar pregnancies |
| Pathology of gynecological tumors associated with hereditary cancer syndromes | |
| Clinicopathological and molecular study of gynecological tumors | |
| Bálint Scheich MD | Complex clinico-pathological and molecular analysis of meningiomas in order to identify and experimentally validate novel prognostic biomarkers and therapeutic targets |
| Anna Sebestyén MD / Dorottya Moldvai MD / Viktória Varga MD | The role of metabolic heterogeneity in tumour progression |
| Tumour model development for basic- and preclinical research, precision drug tests | |
| Heterogeneity in immunmetabolic alterations after immun check point inhibitor therapy | |
| Gábor Szalóki MD | The effect of medicine candidate drugs on FLT3 positive primary AML cell cultures |
| Árpád Szállási MD | New prognostic markers in pancreatic ductal and colorectal carcinoma |
| Vanda Téglási MD | Investigation of the microenvironment in brain metastases of solid tumors |
| Csilla Tolnai-Kriston MD | The assessment of the efficacy of venetoclax-obinutuzumab therapy by flow cytometry in chronic lymphocytic leukemia (CLL) |
Responsible for TDK: Richárd Kiss MD